"5 days"@en . "Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin."@en . "Humans and other mammals"@en . "Raptiva"@en . "hu1124"@en . . "approved"@en . "214745-43-4"@en . . . "Average efalizumab bioavailability following subcutaneous administration was estimated at 30 to 50%."@en . . . "investigational"@en . "Efalizumab binds to CD11a, a subunit of leukocyte function antigen-1 (LFA-1), which is expressed on all leukocytes. As a result efalizumab decreases cell surface expression of CD11a."@en . . . . . "anti alphaL integrin"@en . "Efalizumab"@en . "antiCD11 alpha"@en . . "# \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8943405 # Descamps V: [Efalizumab] Ann Dermatol Venereol. 2006 Aug-Sep;133(8-9 Pt 1):666-78. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17053736"@en . . . " "@en . . "For the treatment of adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy."@en .